Protara Therapeutics, Inc. (NASDAQ:TARA) Shares Bought by Oppenheimer & Co. Inc.

Oppenheimer & Co. Inc. boosted its holdings in shares of Protara Therapeutics, Inc. (NASDAQ:TARA) by 12.4% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 201,426 shares of the company’s stock after buying an additional 22,301 shares during the period. Oppenheimer & Co. Inc.’s holdings in Protara Therapeutics were worth $1,064,000 as of its most recent SEC filing.

Separately, XTX Topco Ltd acquired a new stake in Protara Therapeutics during the 3rd quarter worth approximately $60,000. 38.13% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

TARA has been the topic of a number of analyst reports. HC Wainwright restated a “buy” rating and issued a $23.00 price objective on shares of Protara Therapeutics in a report on Friday, December 6th. Guggenheim restated a “buy” rating and issued a $20.00 price objective on shares of Protara Therapeutics in a report on Friday, December 6th.

Protara Therapeutics Trading Down 2.3 %

Shares of TARA opened at $3.36 on Wednesday. Protara Therapeutics, Inc. has a twelve month low of $1.60 and a twelve month high of $10.48. The firm’s fifty day simple moving average is $4.66 and its 200-day simple moving average is $3.39. The firm has a market capitalization of $69.32 million, a price-to-earnings ratio of -1.19 and a beta of 1.63.

Protara Therapeutics Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.